Key MessagesAfter accounting for the difference in mean blood pressure, there is still a 3--5 percentage-point difference in the prevalence of raised blood pressure across regions, being highest in South Asia and in Central Asia, the Middle East and North Africa, and lowest in the high-income Asia Pacific and high-income Western regions.Shifts in entire distribution of blood pressure have been the main driver of the change in prevalence of raised blood pressure.There is also a measurable contribution from the change in the high-blood-pressure tail of the distribution, towards lowering the prevalence of raised blood pressure, especially in older people.

Introduction
============

Raised blood pressure, commonly defined as systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg, is used to identify individuals at high risk of cardiovascular diseases.[@dyy016-B1] Globally, one in four men and one in five women, totalling 1.13 billion adults, had raised blood pressure in 2015.[@dyy016-B6] One of the global non-communicable disease (NCD) targets adopted by the World Health Organization (WHO) in 2013 is to reduce the prevalence of raised blood pressure by 25% compared with its 2010 level, by 2025.[@dyy016-B7]

The prevalence of raised blood pressure varies substantially across and within regions and countries, with age-standardized adult prevalence in 2015 ranging from 20% in the high-income Asia Pacific region to 33% in Central and Eastern Europe for men, and from 11% in the high-income Asia Pacific region to 28% in sub-Saharan Africa for women.[@dyy016-B6] Prevalence has declined substantially in high-income regions for decades, and is also declining in some middle-income regions; it has been stable or has increased in other low- and middle-income regions.[@dyy016-B6]

Blood pressure is a complex trait, affected by genes, fetal and early childhood nutrition and growth,[@dyy016-B8] adiposity and weight gain,[@dyy016-B9]^,^[@dyy016-B10] diet (especially sodium and potassium intakes),[@dyy016-B9]^,^[@dyy016-B11]^,^[@dyy016-B12] alcohol use,[@dyy016-B10]^,^[@dyy016-B13] smoking,[@dyy016-B14] physical activity,[@dyy016-B10]^,^[@dyy016-B15] air pollution,[@dyy016-B16] lead,[@dyy016-B17] noise,[@dyy016-B18] psychosocial stress,[@dyy016-B19] sleep duration[@dyy016-B20] and the use of blood pressure-lowering medicines. Changes in some of these factors, for example increase in body mass index (BMI) and better nutrition in childhood and adolescence, can shift the entire population distribution of blood pressure, and hence change its mean as well as the prevalence of raised blood pressure. In contrast, the use of antihypertensive medicines and lifestyle change to reduce blood pressure in those with elevated levels would reduce the prevalence of raised blood pressure by acting on the high-blood-pressure tail of the distribution, and hence change the shape of the distribution with a relatively small impact on its mean. An important question that can inform strategies for meeting the global target and reducing the burden of raised blood pressure, is to what extent regional differences and changes over time in the prevalence of raised blood pressure are driven by variations in the mean SBP and DBP versus by the shape of the distribution. We used a database of population-based studies with global coverage conducted over three decades to investigate contributions of population mean and high-blood-pressure individuals to worldwide trends and variations in raised blood pressure.

Methods
=======

Study design
------------

We first used population-based data to estimate the association between the prevalence of raised blood pressure, defined as SBP ≥ 140 mmHg or DBP ≥ 90 mmHg, and population mean SBP and DBP among men and women aged 20 to 79 years in nine regions of the world, from 1985 to 2016. We used a linear mixed effect model to quantify the association between the prevalence of raised blood pressure and mean blood pressure. Our statistical model, described below, allowed the prevalence of raised blood pressure at any level of mean SBP and DBP to differ by age group, region and time period. We then used the fitted association to estimate the contributions of changes in the population mean blood pressure versus changes in the shape of its distribution (represented by how the prevalence-mean association varied over region and time), to the changes in the prevalence of raised blood pressure in different regions.

Data sources
------------

We used data from NCD Risk Factor Collaboration (NCD-RisC) database, which contains studies that had measured blood pressure in representative samples of the national populations or of one or more sub-national regions and communities. NCD-RisC is a worldwide network of health researchers and practitioners whose aim is to document systematically the worldwide trends and variations in NCD risk factors. Our methods for identifying and accessing data sources, and the inclusion and exclusion criteria, are described in recent publications.[@dyy016-B6]^,^[@dyy016-B21] In summary, the database was collated through multiple routes for identifying and accessing data. We accessed publicly available population-based multi-country and national measurement surveys as well as the WHO STEPwise approach to Surveillance (STEPS) surveys. We requested, via WHO and its regional and country offices, ministries of health and other national health and statistical agencies to identify and access population-based surveys. Requests were also sent via the World Heart Federation to its national partners. We made a similar request to the co-authors of an earlier pooled analysis of cardiometabolic risk factors,[@dyy016-B25] and invited them to re-analyse data from their studies and join NCD-RisC. To identify major sources not accessed through the above routes, we searched and reviewed published studies, and invited all eligible studies to join NCD-RisC. Finally, NCD-RisC members are periodically asked to review the list of sources from their country, to suggest additional sources currently not in the database and to verify that the included data from their country meet the inclusion criteria as listed in the [Supplementary data](#sup1){ref-type="supplementary-material"} (available at *IJE* online) and that there are no duplicates. Here, we analysed data collected from 1985 to 2016 on men and women aged 20--79 years, in 10-year age groups from 20--29 years to 70--79 years.

Statistical methods
-------------------

We first calculated mean SBP, mean DBP and prevalence of raised blood pressure for these age groups by sex in each study, taking into account complex survey design and survey sample weights, where relevant. We excluded data points which did not cover complete 10-year age groups, e.g. those in people aged 25--29 years or 60--64 years, to avoid bias in the estimated associations. We also excluded age-sex groups with \< 25 participants, because their means and prevalence have larger uncertainty.

We then estimated the relationship between the prevalence of raised blood pressure and mean, using a linear mixed effect model, shown below in the equation (where *ε* is the error term), separately by sex. We used probit-transformed prevalence because it provided a better fit to the data than a simple linear model or logit transformation. The model included age group (10-year age groups from 20--29 to 70--79) and the decade when the data were collected (1985--94, 1995--2004 or 2005--16). We also included interactions between age group and mean blood pressure, between decade and mean blood pressure, and among these three terms, which allowed the prevalence-mean association to vary by age group and over time. We included regional random intercepts to account for the differences in prevalence at any level of mean SBP and DBP by region. The regions, used in previous analyses of cardiometabolic risk factors,[@dyy016-B6]^,^[@dyy016-B21] were: Central and Eastern Europe; Central Asia, the Middle East and North Africa; East and South-east Asia; high-income Asia Pacific; high-income Western countries; Latin America and the Caribbean; Oceania; South Asia; and sub-Saharan Africa. Countries in each region are listed in [Supplementary Table 1](#sup1){ref-type="supplementary-material"} (available as [Supplementary data](#sup1){ref-type="supplementary-material"} at *IJE* online). The models were fitted in statistical software R version 3.4.2. Goodness of fit of the models was assessed by conditional R^2^, which represents the proportion of variance explained by both fixed and random factors.[@dyy016-B29]$$\begin{array}{l}
{\text{Probit‐transformed\ prevalence\ of\ raised\ blood\ pressure}{= \beta_{0} + \beta_{\text{1}}Mean_{SBP} + \beta_{\text{2}}Mean_{DBP} + \beta_{\text{3}}Age\_ group + \beta_{\text{4}}Decade}} \\
{+ \beta_{\text{5}}Age\_ group \cdot Decade + \beta_{\text{6}}Mean_{SBP}{}_{\operatorname{}} \cdot Age\_ group + \beta_{\text{7}}Mean_{DBP} \cdot Age\_ group} \\
{+ \beta_{\text{8}}Mean_{SBP}{}_{\operatorname{}} \cdot Decade + \beta_{\text{9}}Mean_{DBP} \cdot Decade} \\
{+ \beta_{\text{1}0}Mean_{SBP}\operatorname{} \cdot Age\_ group \cdot Decade + \beta_{\text{11}}Mean_{DBP} \cdot Age\_ group \cdot Decade} \\
{+ Random\_ intercept_{Region}~ + \varepsilon} \\
\end{array}$$

We used a simulation approach to account for the uncertainty in the mean and prevalence data used in fitting the regression. Specifically, we used 1000 draws from the uncertainty distributions of each age- and sex-specific input data point (i.e. mean SBP and DBP and prevalence of raised blood pressure) with uncertainty represented by a normal distribution for mean SBP and DBP and by a binomial distribution for prevalence of raised blood pressure. We then fitted a separate regression to each of the 1000 simulated datasets. We sampled 1000 draws from the joint distribution of the regression coefficients for each of the 1000 fitted regressions (i.e. 1 000 000 sets of regression coefficients). We report the median of the resulting 1 000 000 draws for each coefficient, and their 2.5th and 97.5th percentiles as the 95% confidence interval. We also report the median of conditional R^2^ from the 1000 fitted regressions.

We used the fitted regressions to quantify how much differences across regions, and changes over time in the prevalence of raised blood pressure, were driven by differences/changes in mean SBP and DBP, versus by differences/changes in the prevalence-mean association. We first used the age-sex-specific global mean SBP and DBP in 2010 (∼mid-point of the 2005--16 period) in the fitted association, and estimated the prevalence of raised blood pressure by region. The age-sex-specific mean SBP and DBP values were taken from a recent comprehensive analysis of worldwide trends in blood pressure,[@dyy016-B6] and are listed in the [Supplementary Table 2](#sup1){ref-type="supplementary-material"} (available as [Supplementary data](#sup1){ref-type="supplementary-material"} at *IJE* online). We report the differences between the predicted regional raised blood pressure prevalence and that of the world as a whole. These differences measure how much prevalence would vary across regions---due to geographical variations in the shape of blood pressure distribution---if they had the same population mean blood pressure.

We then decomposed total change in prevalence of raised blood pressure from 1985--94 to 2005--16 into contributions of change in mean SBP and DBP, change in the shape of prevalence-mean association and interaction of the two. The contribution of change in mean was estimated by allowing mean SBP and DBP for each age, sex and region to change over time, while keeping the decade variable fixed at 1985--94. The contribution of change in association was estimated by setting mean SBP and DBP to their 1990 levels (mid-year of 1985--94) for each age, sex and region, and allowing the decade variable to change. The interaction of the two factors is the difference between total change in prevalence and the sum of the above two components. The three components are schematically shown in [Figure 1](#dyy016-F1){ref-type="fig"}.

![Schematic diagram for the contributions of change in mean blood pressure and in shape of the blood pressure distribution to the change in prevalence of raised blood pressure. Each S-shaped curve shows what the prevalence of raised blood pressure would be at different levels of population mean for a specific shape of population distribution. A change in mean without a change in the shape of the distribution (Panel A) would move prevalence along a curve (orange point in Panel D). A change in the shape of the distribution without a change in mean (Panel B) would vertically move prevalence from one curve to another (blue point in Panel D). The combination (Panel C) would move prevalence from one curve to another, as well as along the curve (purple point in Panel D). The figure shows the contributions when raised blood pressure is defined based on one blood pressure (either SBP or DBP). The same concept applies when raised blood pressure is defined based on both SBP and DBP.](dyy016f1){#dyy016-F1}

We repeated the above analyses for each of the 1 000 000 sets of regression coefficients. We report the median of the resulting 1 000 000 estimates as our main result and their 2.5th and 97.5th percentiles as the 95% confidence interval. All analyses were done separately for men and women. Results were calculated by 10-year age groups and then aggregated into two age bands, 20--49 years and 50--79 years, by taking the weighted average of age-specific results; weights from the WHO standard population were used.

Results
=======

Data sources
------------

We used data from 1018 population-based studies with 88 559 656 participants, of whom 86 187 860 were aged 20--79 years, and satisfied the above inclusion criteria ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}, available as [Supplementary data](#sup1){ref-type="supplementary-material"} at *IJE* online). A total of 385 studies were from the high-income Western region, 108 from East and South-east Asia, 107 from Central Asia, the Middle East and North Africa, 106 from Central and Eastern Europe, 83 from sub-Saharan Africa, 79 from Latin America and the Caribbean, 78 from high-income Asia Pacific, 38 from South Asia and 34 from Oceania. The individual-level data were summarized into 7910 age-sex-specific pairs of mean of and prevalence of raised blood pressure. The number of data sources by country is shown in [Figure 2](#dyy016-F2){ref-type="fig"}, and a list of data sources and their characteristics is provided in [Supplementary Table 4](#sup1){ref-type="supplementary-material"} (available as [Supplementary data](#sup1){ref-type="supplementary-material"} at *IJE* online).

![Number of blood pressure data sources from 1985 to 2016 used in the analysis, by country.](dyy016f2){#dyy016-F2}

Association of prevalence of raised blood pressure with mean SBP and DBP
------------------------------------------------------------------------

The coefficients of the regression models are listed in [Supplementary Tables 5 and 6](#sup1){ref-type="supplementary-material"} (available as [Supplementary data](#sup1){ref-type="supplementary-material"} at *IJE* online). Together, mean SBP and DBP, decade, age group and region explained most of the variation in the prevalence of raised blood pressure, evidenced by the high conditional R^2^ statistics of 0.918 for women and 0.871 for men.

Changes in prevalence of raised blood pressure and mean SBP and DBP, by region
------------------------------------------------------------------------------

In 2005--16, the age-standardized prevalence of raised blood pressure in people aged 20--49 years ranged from 4% (95% credible interval: 3--6%) in high-income Asia Pacific to 16% (13--19%) in sub-Saharan Africa in women, and from 14% (11--17%) in high-income Asia Pacific to 25% (21--30%) in Central and Eastern Europe in men. In those aged 50--79 years, the range was from 31% (26--36%) in high-income Asia Pacific to 56% (52--61%) in sub-Saharan Africa in women, and from 40% (36--43%) in the high-income Western region to 57% (51--63%) in Central and Eastern Europe in men.

The prevalence of raised blood pressure decreased substantially from 1985--94 to 2005--16 in the two high-income regions and Central and Eastern Europe in both men and women across all ages ([Figure 3](#dyy016-F3){ref-type="fig"}).[@dyy016-B6] It also decreased in Latin America and the Caribbean, and in Central Asia, the Middle East and North Africa, and marginally in men in sub-Saharan Africa. Over the same period, mean SBP and mean DBP decreased in these regions and sexes, except in men in sub-Saharan Africa, whose mean SBP and DBP increased, and in men in Central Asia, the Middle East and North Africa, whose mean SBP and DBP were unchanged. The prevalence of raised blood pressure and mean SBP and DBP increased in Oceania and South Asia.

![Changes in prevalence of raised blood pressure, mean SBP and mean DBP from 1985--94 to 2005--16, by region, sex and age group.](dyy016f3){#dyy016-F3}

Contributions of mean and shape of blood pressure distribution to regional variations in raised blood pressure
--------------------------------------------------------------------------------------------------------------

Although in 2005--16 the ranking of regions in terms of prevalence of raised blood pressure was largely the same as the ranking of the mean, especially for women, inter-region differences in prevalence were not entirely due to those of mean blood pressure. Rather, some regions had an excess prevalence compared with what would be expected based on their mean, and others a lower prevalence compared with what would be expected based on their mean. At the same level of population mean SBP and DBP as that of the world as a whole, men and women in South Asia and in Central Asia, the Middle East and North Africa would have the highest prevalence of raised blood pressure, about 1--2 percentage points higher than the world average in different age groups ([Figure 4](#dyy016-F4){ref-type="fig"}). In contrast, at the same level of population mean SBP and DBP as that of the world as a whole, high-income Asia Pacific would have the lowest prevalence, followed by the high-income Western region, with prevalence about 1--3 percentage points lower than the world average across different age and sex groups, especially among women. The ordering of regions in terms of excess prevalence was similar between men and women, except for men in Central and Eastern Europe whose ranking in terms of excess prevalence was worse than that of women in the same region.

![Regional differences in prevalence of raised blood pressure among men and women aged 20--49 years and 50--79 years in 2005--16 if every region had the same mean SBP and DBP, equal to the global age-sex-specific mean in 2010. The points show the central estimates and the bars their 95% confidence intervals.](dyy016f4){#dyy016-F4}

Contributions of mean and shape of blood pressure distribution to trends in raised blood pressure
-------------------------------------------------------------------------------------------------

In most regions where sex and age groups experienced a decline in the prevalence of raised blood pressure, the decline in mean blood pressure was the main driver of the decline in prevalence ([Figure 5](#dyy016-F5){ref-type="fig"}). The main exceptions to this distributional shift were men in sub-Saharan Africa and in Central Asia, the Middle East and North Africa, whose mean blood pressure increased or remained unchanged while prevalence declined slightly. Further, in men in Latin America and the Caribbean and in Central and Eastern Europe, change in prevalence-mean association contributed marginally more to prevalence decline than did the decline in mean blood pressure. Elsewhere, the decline in mean blood pressure accounted for 60% or more of the decline in the prevalence of raised blood pressure, with a larger contribution where mean blood pressure declined more, typically in high-income regions. Change in the prevalence-mean association, which represents change in the high-blood-pressure tail of the distribution, was responsible for the majority of the remainder of change in prevalence, and for its entirety among men in sub-Saharan Africa and in Central Asia, the Middle East and North Africa. The contribution of change in prevalence-mean association was larger in those aged 50--79 years than in those aged 20--49 years in most regions, especially for women.

![Contributions of change in mean blood pressure, change in prevalence-mean association, and the interaction of the two, to change in prevalence of raised blood pressure from 1985--94 to 2005--16 by region, sex and age group.](dyy016f5){#dyy016-F5}

The prevalence of raised blood pressure increased among men and women in Oceania and South Asia, and among women in sub-Saharan Africa and men in East and South-east Asia. The increase was driven entirely by rise in mean blood pressure, offset partly by the change in the prevalence-mean association. Prevalence of raised blood pressure remained largely unchanged among women in East and South-east Asia, due to opposing effects of increasing mean and the decrease brought by the changes in prevalence-mean association.

Discussion
==========

We found that the trends and geographical variations in the prevalence of raised blood pressure are largely driven by shifts in the distribution of blood pressure in whole populations, rather than by the shape of the distribution. There was nonetheless an important contribution from having fewer high-blood-pressure individuals at the same level of population mean SBP and DBP over time, especially in older age groups.

Rose and Day[@dyy016-B30] and Laaser *et al.*[@dyy016-B31] used data from the Intersalt Study and from population-based studies in Germany, respectively, and found a strong association between prevalence of raised blood pressure and its mean, as we did, but neither analysis had sufficient data to quantify how the association varied in relation to age, time period or region as was done here. An analysis of data from the multi-country MONICA Project[@dyy016-B32] found that the upper percentiles of blood pressure distribution changed as much as its mean in some communities, and by a larger amount in others. The authors concluded that the decline in blood pressure is mostly a population phenomenon but there was no detailed quantification of the contribution, especially in relation to age, time period or region as was done here with substantially more data. Downward shifts in the whole blood pressure distribution over time have also been reported in a few high-income countries,[@dyy016-B33] with some studies also finding a larger decline in the upper tail than in the mean of the blood pressure distribution, which is consistent with our results.

The strengths of our study include presenting the first global analysis of how much population mean and high-blood-pressure individuals have contributed to worldwide trends and variations in raised blood pressure, using a large global database with data from different regions and over time, and using methods that allowed the prevalence-mean association to vary by sex, age group, time period and region. Despite using the most comprehensive global collection of population-based studies to date, some regions had limited data, especially early in our analysis period. Further, there have been changes over time in devices used for measuring blood pressure in health surveys, with standard mercury sphygmomanometers replaced by random-zero sphygmomanometers and more recently digital oscillometric devices. These changes are unlikely to have affected our regional comparisons, and would only affect prevalence-mean association over time if they had differential effects at high versus low blood pressure.

Although we found that changes in the prevalence of raised blood pressure have been mostly due to whole-distribution shifts, the behavioural, nutritional and environmental drivers of this shift remain uncertain. In high-income countries, the decline in blood pressure has occurred despite the rise in BMI,[@dyy016-B21] which is an established risk factor for high blood pressure, but how the concurrent and at times larger rise in BMI in low- and middle-income countries may be affecting blood pressure is unclear. Salt intake has declined in China[@dyy016-B41] and possibly in some high-income countries,[@dyy016-B42] but has not changed in other countries where blood pressure has declined.[@dyy016-B45] Similarly, prevalence of smoking has declined in most high-income countries and in some middle-income countries but remains high or is increasing in other low- and middle-income regions.[@dyy016-B50] Alcohol consumption has also had mixed trends across countries and regions.[@dyy016-B51] Other potential population-wide drivers of the decline in mean blood pressure which tend to improve with social and economic development include year-round availability of fruits and vegetables, which might increase the amount and regularity of their consumption;[@dyy016-B52] central heating at home and work which would lower winter blood pressure;[@dyy016-B53] and improvements in early childhood and adolescent nutrition, as seen in greater height in successive birth cohorts when they reach adulthood.[@dyy016-B23] A role for such distal determinants with life course impacts is strengthened by the fact that blood pressure is also decreasing in adolescents in high-income countries and possibly some middle-income countries.[@dyy016-B56]

Whereas these determinants act to lower mean blood pressure, better developed health systems are more effective in identifying and treating high-blood-pressure individuals, which would change the tail of the distribution without a major impact on its mean. The role of treatment in reducing the prevalence of high blood pressure has become increasingly important as clinical guidelines have lowered the threshold for diagnosing and treating hypertension, e.g. from having an SBP of 160 mmHg or DBP of 95 mmHg in the 1970s[@dyy016-B61] to an SBP of 140 mmHg or DBP of 90 mmHg,[@dyy016-B4]^,^[@dyy016-B62] and to an SBP of 130 mmHg or DBP of 80 mmHg in the newly released ACC/AHA guidelines.[@dyy016-B3] Over time, regional and international guidelines for diagnosis and treatment of hypertension, which are evaluated as cost-effective,[@dyy016-B2]^,^[@dyy016-B63]^,^[@dyy016-B64] have been developed and a larger share of people with raised blood pressure are treated in high-income countries[@dyy016-B33]^,^[@dyy016-B65] and in some middle-income countries.[@dyy016-B73] Nonetheless, treatment coverage and effectiveness remain low, especially in low-income settings.[@dyy016-B79]^,^[@dyy016-B80] Further, there have been improvements in effectiveness of treatment over time, leading to better control of those with hypertension. It may also be the case that changes in some risk factors, e.g. lower salt intake, have larger benefits for people whose blood pressure is high compared with those with low blood pressure,[@dyy016-B11] hence changing the high-blood-pressure tail of the distribution as well as its mean.

Our results demonstrate that changes in blood pressure both at the population and at the individual level have contributed to lowering raised blood pressure. What factors have spurred the former over the past few decades, however, remain largely unclear, and may be related to societal changes in nutrition, housing and health systems arising from social and economic development and technological progress. They also demonstrate the need for data that go beyond identifying the causes of low or high blood pressure, but also help measure how these factors change over time in worldwide populations. Learning about these factors would inform programmes that can help reverse the rise in the prevalence of raised blood pressure or accelerate its decline in low- and middle-income nations, where prevalence remains the highest, more effectively.
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==================

[Supplementary data](#sup1){ref-type="supplementary-material"} are available at *IJE* online.
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